Kangstem Biotech Reports Positive Phase 2a Results for Stem Cell Knee Osteoarthritis Therapy
The placebo-controlled trial enrolled 113 patients with moderate knee osteoarthritis and tracked pain and knee-function scores 24 weeks after a single intra-articular injection.

Key Points
- Kangstem Biotech presented Phase 2a findings for OSCA, an umbilical cord blood–derived mesenchymal stem cell therapy combined with acellular cartilage matrix for knee osteoarthritis, at ACR Convergence 2026.
- In 113 patients with moderate knee osteoarthritis, the OSCA group showed statistically significant improvements over placebo in pain and knee function scores at 24 weeks.
- Kangstem Biotech plans to pursue an FDA IND submission for overseas trials and continue licensing and co-development discussions with global partners.
Kangstem Biotech announced on November 12 that Phase 2a results for OSCA, its umbilical cord blood–derived mesenchymal stem cell therapy combined with acellular cartilage matrix for knee osteoarthritis, were presented orally at ACR Convergence 2026, the annual meeting of the American College of Rheumatology.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
ACR Convergence addresses research and treatment advances in musculoskeletal conditions including rheumatoid arthritis, autoimmune diseases, and osteoarthritis. The presentation took place on November 11 local time in Orlando, Florida, in a session that also included clinical studies from Amgen, Argenx, and Sobi.
Jae-young Park, professor of orthopedic surgery at CHA Bundang Medical Center, CHA University, and principal investigator of the Phase 2a trial, delivered the oral presentation. According to Kangstem Biotech, the session, sponsored in part by Eli Lilly, Johnson & Johnson, and AbbVie, selected six studies, with OSCA as the only osteoarthritis therapy trial. Around 1,000 attendees were present, with a question-and-answer session following the presentation. The company also held local meetings with overseas partners ahead of the conference.
OSCA is a single intra-articular injection combining umbilical cord blood–derived mesenchymal stem cells with acellular cartilage matrix.
Phase 2a results
According to the clinical study report released in October, the placebo-controlled Phase 2a trial enrolled 113 patients with moderate knee osteoarthritis. At 24 weeks, the OSCA group showed statistically significant improvements over placebo in pain measured by visual analog scale and knee function measured by the International Knee Documentation Committee subjective score. MRI-based joint structure assessment using the Whole-Organ Magnetic Resonance Imaging Score also showed changes in some detailed indicators, including bone marrow lesions.
Kangstem Biotech said it plans to use the conference data to pursue an investigational new drug application with the FDA for overseas clinical trials and to continue technology transfer and co-development discussions with overseas pharmaceutical companies.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Kangstem Biotech’s Stem Cell for Knee Osteoarthritis Phase 2a Reports Significant Results
Corestemchem Secures FDA Agreement on Phase 3b Pathway for ALS Stem Cell Therapy
Personalized Stem Cells’ New Trial Tests Adipose Stem Cell Therapy for Chronic Mild Traumatic Brain Injury
Royan Stem Cell Technology’s New Trial Tests Mesenchymal Stromal Cells for Stroke
CellFiber Opens First International Subsidiary in Philadelphia to Support Cell and Gene Therapy Development
Evia Bio Announces Availability of GMP-Grade DMSO-Free Cryopreservation Media for Mesenchymal Stromal Cells
Porton Advanced Announces FDA Acceptance of Drug Master File for Umbilical Cord Stem Cell-Derived Exosomes
INmune Bio and Uniphar Team Up to Support International Access to Umbilical Cord-Derived Cell Therapy for RDEB







